GlassScriptPhysician profile
Jose L Martinez
NPI 1417191891
$11,352.43
in general payments reported to CMS, 2019-2025
46 companies · $1,826 in 2025
The $1,826 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,559 · 2020: $1,351 · 2021: $1,666 · 2022: $1,337 · 2023: $1,411 · 2024: $2,203 · 2025: $1,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,951 · Travel and Lodging: $464 · Education: $25.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,950.79 |
| Travel and Lodging | $463.81 |
| Education | $25.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,629.92 | 2019-2025 | Airsupra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $1,884.86 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,633.34 | 2019-2025 | Stiolto Respimat, Spiriva, Jascayd |
| Inari Medical, INC. | $1,387.92 | 2021-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Insmed, INC. | $288.37 | 2021-2025 | Arikayce, Brinsupri |
| Viatris Specialty LLC | $277.90 | 2025 | Yupelri |
| Mylan Specialty L.P. | $271.15 | 2020-2024 | Yupelri |
| Genzyme Corporation | $268.28 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $243.68 | 2019-2025 | Dupixent |
| Amgen INC. | $196.53 | 2021-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $160.23 | 2019-2023 | Zerbaxa, Keytruda |
| Pfizer INC. | $157.04 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $149.76 | 2020-2024 | Xarelto |
| La Jolla Pharmaceutical Company | $116.45 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $115.43 | 2019 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.